Q-omics provides the consensus-scored ACTE1P profile across patient tissues and cancer cell-line models. ACTE1P expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ACTE1P is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, ACTE1P RNA expression shows 6,715 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, BRCA, and STAD as cancer lineages where ACTE1P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACTE1P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACTE1P survival associations across molecular data types. ACTE1P RNA expression shows survival associations in the most cancer types (20), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACTE1P RNA expression–survival associations across cancer types. High ACTE1P expression shows unfavorable associations in KIRC, CHOL, KICH, ACC and READ, but favorable associations in BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ACTE1P RNA expression.
This table summarizes ACTE1P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for ACTE1P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACTE1P shows lower tumor expression in HNSC and higher tumor expression in BRCA, LIHC and LUSC. The BRCA box plot shows higher ACTE1P RNA expression in tumor versus normal tissue (log2 FC = +0.022, t-test p = .019).
This table shows molecular features associated with ACTE1P in patient tissues and cancer cell lines. In patient samples, ACTE1P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
